



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/780,937	02/18/2004	Tracee Eidenschink	1001.2262101	1924		
28075	7590	11/09/2009	EXAMINER			
CROMPTON, SEAGER & TUFTE, LLC			BUI, VY Q			
1221 NICOLLET AVENUE			ART UNIT			
SUITE 800			PAPER NUMBER			
MINNEAPOLIS, MN 55403-2420			3773			
MAIL DATE		DELIVERY MODE				
11/09/2009		PAPER				

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/780,937	EIDENSCHINK ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Vy Q. Bui	3773	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 17 June 2009.  
 2a) This action is **FINAL**.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-40 is/are pending in the application.  
 4a) Of the above claim(s) 11-16, 19, 21-24 and 34-40 is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1-10, 17, 18, 20 and 25-33 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date <u>3/24/2009</u> .	6) <input type="checkbox"/> Other: _____ .

## **DETAILED ACTION**

### ***Election/Restrictions***

Applicant's election without traverse of invention of species 2 shown in F 11 in the reply filed on 12/12/2008 is acknowledged.

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-8, 17-18, 29-30 are rejected under 35 U.S.C. 102(b) as being anticipated by Bleam et al-6,143,016.

As to claims 1-8, 17-18, 29-30, Bleam-'016 (F 1-12; C 5, L 24-58) discloses balloon catheter 14 comprising catheter shaft 15, balloon 22, 1<sup>st</sup> rotatable sheath 34 of a elastomeric polymer (C 5, L 38-43), balloon catheter 14 as 1<sup>st</sup> guidewire housing having lumen 24 for receiving 1<sup>st</sup> guidewire 26 (F 1, for example) and stents 12a, 12b and 12c (F 13) disposed over rotatable sheath 34 substantially as recited in the claims.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 9-10, 20, 25-28, 31-33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bleam et al-6,143,016.

As to claims 9-10, Bleam-'016 discloses substantially the claimed invention, except for diameter of the stent in a collapsed stent state at the proximal end region is either smaller than a body portion or tapered. It would have been obvious to one of ordinary skill in the art to provide the stent with either reduced diameter or tapered diameter at the proximal end of the stent in the collapsed state as recited in the claims as this configuration would prevent the proximal end of the stent to injure a blood vessel wall during deployment of the stent.

As to claims 20, 25, Bleam-'016 discloses substantially the claimed invention, except for different therapeutic agents for a local treatment of a blood vessel. However, the therapeutic materials are well known for treatment a blood vessel. It would have been obvious to one of ordinary skill in the art to provide a therapeutic agent as recited in the claims as these agents are well known for treatment a blood vessel.

As to claims 26-28, Bleam-'016 discloses substantially the claimed invention, except for a lubricious coating, a hydrophilic coating or a tecophilic coating. However, these coating are well known to use for a catheter device to facilitate the deployment of a catheter in a blood vessel. It would have been obvious to one of ordinary skill in the art to provide a lubricious coating, a hydrophilic coating or a tecophilic coating as recited in the claims as these coatings are well known for use with a catheter to facilitate a deployment of the catheter in a blood vessel.

As to claims 31-33, Bleam-'016 discloses substantially the claimed invention, except for a material as recited in the claims. However, these materials are well known to use for making a catheter device to facilitate the deployment of a catheter in a blood vessel. It would have been obvious to one of ordinary skill in the art to provide these materials as recited in the claims

as these materials are well known to use for a catheter to facilitate a deployment of the catheter in a blood vessel.

***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vy Q. Bui whose telephone number is 571-272-4692. The examiner can normally be reached on Monday-Tuesday and Thursday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jackie Ho can be reached on 571-272-4696. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Vy Q. Bui/  
Primary Examiner, Art Unit 3773